Hans Tillmann

12PUBLICATIONS
17CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsHaematologyComputational logic and formal languagesPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Dec 04, 2025
Hepatic Effects, Potential Drug-Induced Liver Injury, and Other Liver Safety Considerations of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in the New Era of Expanding Non-oncology Indications: Literature Review and Expert Consensus.

Anna Fettiplace, Arie Regev, Alexandre Kiazand

|Sep 20, 2024
Review article: Recommendations for detection, assessment and management of suspected drug-induced liver injury during clinical trials in oncology patients.

Anna Fettiplace, John Marcinak, Michael Merz

|Oct 27, 2023
Size Matters! Anti-HBs Titer and HBV Reactivation During Anti-TNF Therapy.

Shiva Poola, MaryKate Kratzer, Kerry Sewell

|Sep 29, 2022
A novel quantitative computer-assisted drug-induced liver injury causality assessment tool (DILI-CAT).

Hans L Tillmann, Ayako Suzuki, Michael Merz

|Mar 10, 2022
A novel phenotype-based drug-induced liver injury causality assessment tool (DILI-CAT) allows for signal confirmation in early drug development.

Richard P Hermann, Don C Rockey, Ayako Suzuki

|Oct 13, 2020
Hepatitis B surface antibody titres and hepatitis B reactivation with direct-acting antiviral therapy for hepatitis C.

Shiva Poola, Sirish Sanaka, Kerry Sewell

Pageof 2

Frequent Collaborators

2 joint publications

Don Rockey

2 joint publications

Anna Fettiplace

2 joint publications

Arie Regev

2 joint publications

Adrian M Di Bisceglie